Dose-related cardiovascular and endocrine effects of transdermal nicotine

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 1, 1998, Pages 87-95

  Zevin, Shoshana ^b   Jacob III, Peyton ^b   Benowitz, Neal L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALDOSTERONE; CARBOXYHEMOGLOBIN; CATECHOLAMINE DERIVATIVE; COTININE; NICOTINE; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; HEART RATE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; SUBSTITUTION THERAPY; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADULT; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CROSS-OVER STUDIES; ENDOCRINE SYSTEM; GANGLIONIC STIMULANTS; HEART RATE; HUMANS; MALE; MIDDLE AGED; NICOTINE; SINGLE-BLIND METHOD; SMOKING;

EID: 0031849855     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90026-1     Document Type: Article

References (37)

1. Baron JA. Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br Med Bull 1996;52:58-73.
2. Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996;36:597-613.
3. Benowitz NL. Drug therapy: pharmacologie aspects of cigarette smoking and nicotine addition. N Engl J Med 1988;319:1318-30.
4. McBride PE. The health consequences of smoking: cardiovascular diseases. Med Clin North Am 1992;76:333-53.
5. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997;29:1422-31.
6. Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol 1993;22:1159-67.
7. Dacosta A, Guy JM, Tardy B, Gonthier R, Denis L, Lamaud M, et al. Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J 1993;14:1709-11.
8. Warner JG Jr, Little WC. Myocardial infarction in a patient who smoked while wearing a nicotine patch [letter]. Ann Intern Med 1994;120:695.
9. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994;154:989-95.
10. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792-8.
11. Mahmarian JJ, Moye LA, Nasser GA, Nagueh SF, Bloom MF, Benowitz NL, et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol 1997;30:125-30.
12. Benowitz NL, Jacob P III, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994;268:296-303.
13. Paoletti P, Fomai E, Maggiorelli F, Putoni R, Viegi G, Carrozzi L, et al. Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch. Eur Respir J 1996;9:643-51.
14. Benowitz NL. Nicotine replacement therapy: what has been accomplished - can we do better? Drugs 1993;45: 157-70.
15. James JR, Villanueva HF, Johnson JH, Arezo S, Rosecrans JA. Evidence that nicotine can acutely desensitize central nicotinic acetylcholinergic receptors. Psychopharmacology (Berl) 1994;! 14:456-62.
16. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy: percentage of replacement and smoking cessation. JAMA 1995;274:1353-8.
17. Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G, et al. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology (Berl) 1995;122:215-22.
18. Jacob P III, Wilson M, Benowitz NL. Improved gas Chromatographie method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr 1981;222:61-70.
19. Higa ST, Suzuki T, Hayashi A, Tsuge I, Yamamura Y. Isolation of catecholamines in biological fluids by boric acid gel. Anal Biochem 1977;77:18-24.
20. Anton AH, Sayre DF. A study of the factors affecting the aluminium oxide-trihydroxy-indole procedure for the analysis of catecholamines. J Pharmacol Exp Ther 1962;138:360-75.
21. Benowitz NL, Jacob P III. Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking. J Pharmacol Exp Ther 1990;254:1000-5.
22. Benowitz NL, Jacob P III, Jones RT, Rosenberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 1982;221:368-72.
23. Moreyra AE, Lacy CR, Wilson AC, Kumar A, Kostis JB. Arterial blood nicotine concentration and coronary vasoconstrictive effect of low-nicotine cigarette smoking. Am Heart J 1992;124:392-7.
24. Porchet HC, Benowitz NL, Sheiner LB. Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther 1988;244:231-6.
25. Benowitz NL, Kuyt F, Jacob P III. Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking. Clin Pharmacol Ther 1984;36:74-81.
26. Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 1997;62:453-63.
27. Benowitz NL, Jacob P III, Yu L. Daily use of smokeless tobacco: systemic effects. Ann Intern Med 1986; 111:112-6.
28. Bullock AE, Barke KE, Schneider AS. Nicotine tolerance in chromaffin cell cultures: acute and chronic exposure to smoking-related nicotine doses. J Neurochem 1994;62: 1863-9.
29. Skowronski RJ, Feldman D. Inhibition of aldosterone syn-hesis in rat adrenal cells by nicotine and related constituents of tobacco smoke. Endocrinology 1994;134:2171-7.
30. Patel KP, Zhang PL, Mayhan WG. Blunting of renal excretory responses to acute volume expansion by nico-tine: role of enal nerves. J Pharmacol Exp Ther 1995;274:1174-81.
31. Duthie GG, Arthur JR, Beattie JA, Brown KM, Morrice PC, Robertson JD, et al. Cigarette smoking, antioxidants, lipid peroxidation, and coronary heart disease. Ann NY Acad Sci 1993;686:120-9.
32. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88:2149-55.
33. Freeman DJ, Griffin BA, Murray E, Lindsay GM, Gaffney D, Packard CJ, et al. Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subtrac-tion distribution Eur J Clin Invest 1993;23:630-40.
34. Kiowski W, Linder L, Stoschitzky K, Pfisterer M, Burckhardt D, Burkart F, et al. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 1994;90:27-34.
35. Hellerstein MK, Benowitz NL, Neese RA, Schwartz J, Hoh R, Jacob P III, et al. Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J Clin Invest 1994;93:265-72.
36. Thomas GA, Davies SV, Rhodes J, Russell MA, Feyerabend C, Sawe U. Is transdermal nicotine associated with cardiovascular risk? J R Coll Physicians Lond 1995;29: 392-6.
37. Quensel M, Agardh CD, Nilsson-Ehle P. Nicotine does not affect plasma lipoprotein concentrations in healthy men. Scand J Clin Lab Invest 1989;49:149-53.